The treatment of urinary tract infections and use of ciprofloxacin extended release
- PMID: 16634690
- DOI: 10.1517/13543784.15.5.519
The treatment of urinary tract infections and use of ciprofloxacin extended release
Erratum in
- Expert Opin Investig Drugs. 2006 Sep;15(9):1129
Abstract
Urinary tract infections (UTIs) are one of the most common reasons people seek medical attention. There are > 50% of women who will have at least one UTI during their lifetime and most of these will require a physician visit and antibiotic treatment. The high prevalence continues to the in-patient setting where genitourinary infections are the most common nosocomial infection. The efficient diagnosis and effective treatment of UTIs is a major healthcare concern. Factors such as economic efficiency and emerging resistance are increasingly becoming more important considerations in providing patient care. In out-patient uncomplicated UTIs, Escherichia coli has been implicated in < or = 75-90% of cases. Although the prevalence in the in-patient setting decreases, E. coli is still the most common bacteria identified and present in 21-54% of urinary isolates. Trimethoprim-sulfamethoxazole has been the preferred first-line agent for uncomplicated out-patient UTIs where local resistance is < 10 - 20%. In recent years, resistance has superseded this threshold in most regions of the US and Europe. In these areas with increased resistance, fluoroquinolones have become a common first-line agent. Ciprofloxacin has been one of the most widely used fluoroquinolones and has a well-known safety profile, as well as excellent activity against most of the common uropathogens. Ciprofloxacin extended release (ER) is a recently released once-daily formulation that has been increasingly used with good clinical success. The pharmacokinetic and pharmacodynamic parameters of ciprofloxacin ER are shown to be at least equal to twice-daily ciprofloxacin and may even confer superiority as ciprofloxacin ER achieves a higher maximum serum concentration. This is supported by clinical studies, which have shown at least as effective clinical cure and bacteriological eradication rates. These studies have also demonstrated similar tolerability and side-effect profiles. Ciprofloxacin ER combines traditional ciprofloxacin's proven track record of efficacy and safety with favourable pharmacokinetics and convenient once-daily dosing. Increased patient compliance is associated with decreased treatment failures and can help slow the development of antimicrobial resistance. Economic considerations are also increasingly important and providing convenient and effective treatment leading to high clinical success decreases overall costs.
Similar articles
-
Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections.Int J Antimicrob Agents. 2004 Mar;23 Suppl 1:S54-66. doi: 10.1016/j.ijantimicag.2003.12.005. Int J Antimicrob Agents. 2004. PMID: 15037329 Review.
-
Current issues in the management of urinary tract infections: extended-release ciprofloxacin as a novel treatment option.Drugs. 2004;64(6):611-28. doi: 10.2165/00003495-200464060-00004. Drugs. 2004. PMID: 15018591 Review.
-
Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women.Clin Ther. 2002 Dec;24(12):2088-104. doi: 10.1016/s0149-2918(02)80099-6. Clin Ther. 2002. PMID: 12581547 Clinical Trial.
-
Efficacy and safety of a novel once-daily extended-release ciprofloxacin tablet formulation for treatment of uncomplicated urinary tract infection in women.Antimicrob Agents Chemother. 2005 Oct;49(10):4137-43. doi: 10.1128/AAC.49.10.4137-4143.2005. Antimicrob Agents Chemother. 2005. PMID: 16189090 Free PMC article. Clinical Trial.
-
Ciprofloxacin extended release: in the treatment of urinary tract infections and uncomplicated pyelonephritis.Drugs Aging. 2004;21(1):55-64; discussion 65-6. doi: 10.2165/00002512-200421010-00005. Drugs Aging. 2004. PMID: 14715044 Review.
Cited by
-
The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic.Front Public Health. 2022 Dec 21;10:1025633. doi: 10.3389/fpubh.2022.1025633. eCollection 2022. Front Public Health. 2022. PMID: 36620240 Free PMC article. Review.
-
Pattern of Antibacterial Resistance in Urinary Tract Infections: A Systematic Review and Meta-analysis.Int J Prev Med. 2019 Oct 9;10:169. doi: 10.4103/ijpvm.IJPVM_419_17. eCollection 2019. Int J Prev Med. 2019. PMID: 32133087 Free PMC article. Review.
-
Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections.Antimicrob Agents Chemother. 2018 Mar 27;62(4):e02317-17. doi: 10.1128/AAC.02317-17. Print 2018 Apr. Antimicrob Agents Chemother. 2018. PMID: 29339395 Free PMC article. Clinical Trial.
-
Clinical Efficacy and Residue Depletion of 10% Enrofloxacin Enteric-Coated Granules in Pigs.Front Pharmacol. 2017 May 23;8:294. doi: 10.3389/fphar.2017.00294. eCollection 2017. Front Pharmacol. 2017. PMID: 28588496 Free PMC article.
-
Evaluation of Rational Drug Use for Acute Pharyngitis Associated with the Incidence and Prevalence of the Disease at Two Community Health Centers in Indonesia.Sci Pharm. 2017 Apr 28;85(2):22. doi: 10.3390/scipharm85020022. Sci Pharm. 2017. PMID: 28452967 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical